We’re developing a pipeline of diagnostics and therapeutics for amyloid diseases based on our unique platform, starting with Alzheimer’s disease and Parkinson’s disease.
Targeting the toxic soluble oligomers for the early detection of amyloid diseases.
Targeting the toxic soluble oligomers for the early treatment of amyloid diseases.
Alzheimer’s Disease (AD)
In the U.S., a new case of dementia is diagnosed every six minutes, and these diseases are not unique to the U.S. Dementia is diagnosed every three seconds worldwide and its annual global cost is estimated to exceed US $1 trillion.
AD can develop undetected for 10-20 years. Current treatment options for AD only offer symptomatic relief and most therapies in development target the downstream events caused by the toxic soluble oligomers. There is an urgent need for early diagnosis and treatment of Alzheimer’s Disease (AD). AltPep aims to change that with its SOBA diagnostic and SOBIN therapeutic.
Parkinson’s Disease (PD)
Parkinson’s is the second most common neurodegenerative disease (behind AD) and the fastest growing. PD affected over 1 million adults in the US in 2020. By 2040, the number of people with PD worldwide is estimated to exceed 12 million. The effect of PD on patients’ qualify of life is one of the most severe of all chronic diseases.
There is no definitive test to diagnose PD. By the time motor symptoms emerge, significant neurological damage has already occurred. Treatment options for PD only offer symptomatic relief and the effectiveness of these treatments often decreases over time. The goal for the SOBA diagnostic to identify patients with PD before motor symptoms emerge and for the SOBIN therapeutic to be used for early disease-modifying treatment of PD.